Clinical trials: Acute Decompensated Heart Failure
Acute Decompensated Heart Failure
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure…
- Trial name
- FASTR (NCT05174312)
- Testing
- Reprieve Decongestion Management System, Diuretic
- Where
- 16 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reprieve Cardiovascular, Inc
Congestive Heart Failure
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00559650
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 72 sites in United States, Canada and 15 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Heart Failure
Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy
The purpose of this clinical study is to evaluate the safety and clinical effectiveness of use of a physician-directed, patient self-management system, guided by left atrial pressure measurements, for use in patients with heart…
- Trial name
- LAPTOP-HF (NCT01121107)
- Testing
- Left Atrial Pressure Monitoring System, Patient Advisory Module
- Where
- 64 sites in United States, New Zealand
- Volunteers
- 486 people
- Sponsor
- Abbott Medical Devices
Congestive Heart Failure
TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated Fluid Management System
This is a prospective, single arm, early feasibility study designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart failure…
- Trial name
- NCT03897842
- Testing
- Reprieve Cardiovascular System
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- CardioRenal Systems, Inc.
Chronic Heart Failure
Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure
This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
- Trial name
- NCT00057356
- Testing
- conivaptan
- Where
- 26 sites in United States
- Volunteers
- 170 people
- Sponsor
- Cumberland Pharmaceuticals
Heart Failure, Acute Decompensated Heart Failure
Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance
- Conditions
- Heart Failure, Acute Decompensated Heart Failure, Cardiorenal Syndrome, Heart Failure, Congestive
- Trial name
- NCT06174623
- Testing
- ModulHeart Support
- Where
- 5 sites in Australia, Georgia
- Volunteers
- 5 people
- Sponsor
- Puzzle Medical Devices Inc.
Heart Failure, Congestive, Heart Decompensation
Registry for Acute Decompensated Heart Failure Patients
The purpose of the ADHERE study is to develop a multi-center, observational, open-label registry of the management strategies of patients treated in the hospital for acute Heart Failure in the United States.
- Trial name
- NCT00366639
- Testing
- Acute Decompensated Heart Failure
- Volunteers
- 24,118 people
- Sponsor
- Scios, Inc.
Heart Failure, Congestive
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated heart failure (ADHF) patients by re-establishing…
- Trial name
- NCT02135861
- Testing
- DCE-MRI scans, Gadobutrol
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study.
- Trial name
- NCT01096043
- Testing
- Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
Symptomatic Decompensated Congestive Heart Failure, Congestive Heart Failure in Acute Coronary Syndrome
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
The purpose of this study is to compare the hemodynamic (blood flow) and clinical effects of the study drug, Natrecor (nesiritide, a recombinant form of the natural human peptide normally secreted by the heart in response to…
- Trial name
- NCT00270374
- Testing
- nesiritide
- Volunteers
- 498 people
- Sponsor
- Scios, Inc.
Heart Failure, ADHF
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
- Conditions
- Heart Failure, ADHF, Chronic Heart Failure, CHF
- Trial name
- NCT01316432
- Testing
- Cenderitide
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Nile Therapeutics
Heart Failure, Congestive
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects hospitalized with symptomatic acute decompensated heart failure (ADHF).
- Trial name
- NCT00487799
- Testing
- Ularitide
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Facet Biotech
Acute Heart Failure
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 2 (NCT01067859)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 30 sites in United States, Argentina and 7 more
- Volunteers
- 5 people
- Sponsor
- Bayer
Acute Decompensated Heart Failure
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure…
- Trial name
- FASTR-II (NCT06898515)
- Testing
- Reprieve System, furosemide infusion
- Where
- 50 sites in United States, Germany and 3 more
- Volunteers
- 400 people
- Sponsor
- Reprieve Cardiovascular, Inc
Heart Decompensation, Congestive Heart Failure
An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure
The present study was an open-label, uncontrolled, and multi-centered phase III clinical trial for evaluation of the efficacy (clinical efficacy and hemodynamics) and safety of nesiritide.
- Trial name
- NCT00813202
- Testing
- Nesiritide
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Acute Decompensated Heart Failure
Cardionomic STOP-ADHF Study
STOP-ADHF Study: An evaluation of the safety and performance of the Cardionomic Cardiac Pulmonary Nerve Stimulation (CPNS) system in patients with acute decompensated heart failure.
- Trial name
- NCT04814134
- Testing
- CPNS Therapy, Standard of care
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 59 people
- Sponsor
- Cardionomic Inc.
Acute Heart Failure
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 1 (NCT01065077)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 59 sites in United States, Austria and 15 more
- Volunteers
- 12 people
- Sponsor
- Bayer
Cardiogenic Shock, Acute Decompensated Heart Failure
SURPASS Impella 5.5 Study
A multi-center, prospective \& retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of…
- Trial name
- NCT05100836
- Testing
- Impella 5.5
- Where
- 15 sites in United States
- Volunteers
- 1,017 people
- Sponsor
- Abiomed Inc.
Heart Failure With Preserved Ejection Fraction (HFpEF)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days…
- Trial name
- PARAGLIDE-HF (NCT03988634)
- Testing
- sacubitril/valsartan, valsartan
- Where
- 97 sites in United States, Canada
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals